Krystal Biotech, Inc. (KRYS): Total Liabilities
$114.23M
As of 2025-12-31
$141.52M
As of 2026-06-30
+46.7%
3-year compound annual growth
+43.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $114.23M | +4.4% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $109.46M | +175.6% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $39.71M | +9.6% | 2025-02-19, Balance as of period end |
| 2022-12-31 | $36.22M | +10.7% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $32.72M | +74.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $18.76M | +207.1% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $6.11M | +111.4% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $2.89M | +351.6% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $640.0K | -66.2% | 2018-03-12, Balance as of period end |
| 2016-12-31 | $1.89M | n/a | 2018-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗